neuroClues
Category: AI in Healthcare
French-Belgian medtech company developing a portable, AI-powered eye-tracking device (CE-marked Class IIa) that extracts objective neurological biomarkers from eye movements to support early diagnosis of Parkinson's, Alzheimer's, and other neurodegenerative diseases. neuroClues was founded in 2020. The company is led by Antoine Pouppez. Based in Louvain-la-Neuve, Belgium (with office in Bordeaux, France; presence at Paris Brain Institute). Total funding raised: $27.5M. Latest round: Series A. Key investors include Teampact Ventures, White Fund, EIC Fund (European Innovation Council), Invest.BW, Leansquare, Wallonie Entreprendre, Graph Ventures, Artwall, Olivier Legrain (CEO of IBA).
- Founded
- 2020
- Headquarters
- Louvain-la-Neuve, Belgium (with office in Bordeaux, France; presence at Paris Brain Institute)
- Total funding
- $27.5M
Value proposition
Replaces the subjective 60-year-old "follow my finger" test with objective, quantified, reproducible eye-movement biomarkers. Enables earlier detection of Parkinson's, Alzheimer's, and other neurological conditions — when up to 65% of neurons are already lost by the time of conventional diagnosis. Portable, plug-and-play, integrates into standard consultation workflow with results in minutes.
Products and solutions
neuroClues® — a portable, CE-marked Class IIa medical device that captures high-speed infrared images (800 fps) of both eyes while patients perform simple visual tasks. Proprietary AI algorithms compute objective, reproducible neurological biomarkers from eye movements within a 10-minute exam. Includes hardware headset, software analysis platform, and cloud infrastructure.
Unique value
Only portable eye-tracking device recording at 800 fps (near research gold-standard of 1,000 fps) with proprietary AI algorithms, CE-marked as Class IIa medical device, deployed across 7 European countries within months of certification. Backed by 80,000+ published research papers linking eye movements to neurological conditions.
Target customer
Neurologists, neuro-ophthalmologists, university hospitals, private neurology practices, and research centers. Future expansion to general practitioners and vision professionals for screening.
Industries served
Neurology / Neurodegenerative disease diagnostics, MedTech, Clinical research
Technology advantage
CE-marked Class IIa medical device under MDR; ISO 13485:2016 (quality management) and ISO 27001:2022 (information security) certified; proprietary AI algorithms for oculomotor biomarker computation; 800 fps infrared eye-tracking hardware; integrated into large clinical cohorts (Paris Brain Institute Iceberg study); strong IP portfolio (2 hardware, 2 electronics, 1 AI, 2 design patents + 4 trademarks)
How they differentiate
1) Dedicated custom hardware (not off-the-shelf VR headsets) with 800 fps capture speed — unmatched in portable clinical devices. 2) Proprietary AI algorithms for biomarker computation. 3) CE-marked Class IIa medical device with regulatory clearance. 4) Integrated into major clinical cohorts (Paris Brain Institute Iceberg study, 25,000-participant normative database). 5) Strong IP portfolio with 2 hardware patents, 2 electronics patents, 1 AI patent, 2 design patents, 4 trademarks. 6) Backed by top-tier European institutional investors and EIC Accelerator.
Main competitors
NeuraLight, RightEye, Neurosync, Tobii Dynavox, WIVI Vision, Suricog, BrainEye
Key partnerships
Paris Brain Institute (ICM) — Iceberg study on Parkinson's disease, Bpifrance National Prevention Accelerator, French presidential delegation to India (strategic partnerships with AIIMS), Medtronic (MedLim accelerator program), iPEPS incubator at Paris Brain Institute, EIC Accelerator (European Commission)
Notable customers
University hospitals across France, Belgium, Italy, Germany, Switzerland, Netherlands, and UK (30+ devices deployed), Paris Brain Institute (La Salpêtrière Hospital), 25,000-participant mega-cohort for normative oculomotor database
Major milestones
2020: Company founded (P3Lab SRL), 2021: €4.7M Seed round, 2022: ISO 13485:2016 certification + €2.5M EIC Accelerator grant (up to €9M equity), 2023: Integration into Paris Brain Institute Iceberg cohort, 2024: €5M Pre-Series A round, 2025: CE certification (Class IIa) obtained in January, 2025: Deployed 30+ devices across 7 European countries, 2026: €10M Series A led by Teampact Ventures, White Fund, EIC Fund (total raised €25M), 2026: Appointed Bart Stulens (ex-Medtronic VP) as CCO
Growth metrics
30+ devices deployed across 7 European countries within months of CE certification (Jan 2025); growing inbound demand from clinicians; team grown to ~30+ employees
Market positioning
European leader in AI-powered oculomotor biomarkers for neurodegenerative disease diagnosis. Positioned as the "stethoscope of the brain" — a non-invasive, objective diagnostic tool for neurologists. Currently deployed across 7 European countries with sights set on US market entry (FDA submission in progress).
Geographic focus
Europe (France, Belgium, Italy, Germany, Switzerland, Netherlands, UK) with planned US expansion
Patents and IP
2 hardware patents (product envelope and working principle); 2 embarked electronics patents (screen and cameras); 1 AI patent (video analysis principles); 1 paradigm patent; 4 trademarks; 2 design patents (UI and mechanical design)
About Antoine Pouppez
Bioengineer (Université libre de Bruxelles); former IBA employee; dedicated to medical device field with a track record of converting ideas into reality.
Latest news about neuroClues
More AI in Healthcare companies
Official website: https://neuroclues.com